<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757521</url>
  </required_header>
  <id_info>
    <org_study_id>201509128</org_study_id>
    <nct_id>NCT02757521</nct_id>
  </id_info>
  <brief_title>Nitrous TRD Bipolar Depression</brief_title>
  <official_title>Nitrous Oxide - A Novel Therapy for Treatment-Resistant Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will study approximately 64 patients with Treatment-Resistant Bipolar
      Depressive Disorder, defined as a failure of at least 1 antidepressants in the current
      depressive episode and 2 lifetime medication failures. The study will last approximately 6 to
      8 weeks, involving randomization into one of two treatment groups receiving 3 one hour long
      inhalation treatments over a week.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will study approximately 64 patients with Treatment-Resistant Bipolar
      Depressive Disorder, defined as a failure of at least 1 antidepressants in the current
      depressive episode and 2 lifetime medication failures. The study will last approximately 6 to
      8 weeks, involving randomization into one of two treatment groups receiving 3 one hour long
      inhalation treatments over a week. Post-treatment assessments follow each inhalation
      treatment and are conducted 1 week and 2 weeks following the final inhalation treatment.
      Patients are then randomized again into the Second Stage of the study, involving the same
      treatment and post-treatment schedule as the First Stage detailed above.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study sponsor ended trial due to low recruitment
  </why_stopped>
  <start_date type="Actual">March 25, 2016</start_date>
  <completion_date type="Actual">December 6, 2016</completion_date>
  <primary_completion_date type="Actual">December 6, 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MADRS (Montgomery Asberg Depression Rating Scale)</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Change in depressive symptoms on MADRS scale between baseline and day 7 follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale-17 Item (Ham-D17)</measure>
    <time_frame>up to1week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS) to Assess Emergence of Mania/Hypomania</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Young Mania Rating Scale (YMRS) to assess emergence of mania/hypomania (patients with YMRS scores &gt; 12 will be removed from the trial and recommended for follow up treatment per Psychiatry P.I., i.e., nitrous oxide treatments discontinued)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Profile of Mood States (POMS) Short Form to Assess for Rapid/Instantaneous Changes in Mood/Affect</measure>
    <time_frame>up to 1 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quick Inventory of Depressive Symptomatology- Self Report (QIDS -SR) Patient-rated Depression Measure</measure>
    <time_frame>up to 1 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinician Administered Dissociative States Scale (CADSS) for Emergence of Disassociation</measure>
    <time_frame>up to 1week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS) to Assess Psychotic or Hallucinogenic Behavior</measure>
    <time_frame>up to 1 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Scale for Suicidal Ideation (SSI) to Assesses for Emergence of Suicidal Thinking</measure>
    <time_frame>up to 1 week</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Treatment- Resistant Bipolar Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Bipolar Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous Oxide</intervention_name>
    <description>50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <other_name>Laughing Gas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18-65 years of age

          -  Treatment-resistant bipolar depressive disorder without psychosis and a MADRS baseline
             score of &gt;20. All patients must have history of being on a serum-verified (at time of
             entry into study) mood stabilizer [lithium at 0.5-1.2mEq/L; or valproic acid,
             50-125mcg/ml] for 4 weeks prior to entry into the study and remain on this mood
             stabilizer during the course of the trial. Further, subjects will have failed two
             adequate dose/duration antidepressant courses in their lifetime, including one in the
             current depressive episode (verified by Antidepressant Treatment History Form).

          -  Good command of the English language

        Exclusion Criteria:

          -  Schizophrenia

          -  Schizoaffective disorder

          -  Obsessive-compulsive disorder or panic disorder

          -  Active or recent substance abuse or dependence (in remission at least 1 year prior to
             the study; exception = nicotine use disorders)

          -  A diagnosis of personality disorder that may interfere with the patient's ability to
             improve on nitrous oxide as determined by study investigator

          -  Acute medical illness that may pose subject at risk during nitrous oxide
             administration (neurological disorders or medical disorders including dementia,
             stroke, encephalopathy, Parkinson's Disease, brain tumors, multiple sclerosis, seizure
             disorder, severe cardiac disease, any disease known to affect drug metabolism and
             excretion, i.e. renal or liver disease) per P.I. discretion

          -  Active suicidal intention (inability to contract for safety)

          -  Active psychotic symptoms

          -  Patients with significant pulmonary disease and/or requiring supplemental oxygen

          -  Contraindication against the use of nitrous oxide: pneumothorax; bowel obstruction;
             middle ear occlusion; elevated intracranial pressure; chronic cobalamin and/or folate
             deficiency treated with folic acid or vitamin B12; pregnant patients; breastfeeding
             women; previous administration of NMDA-receptor antagonists (e.g., ketamine); current
             electro-convulsive therapy treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Palanca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <results_first_submitted>April 10, 2019</results_first_submitted>
  <results_first_submitted_qc>April 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Depressive Disorder</keyword>
  <keyword>Treatment- Resistant Bipolar Disorder</keyword>
  <keyword>Nitrous Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02757521/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Placebo: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
        </group>
        <group group_id="P2">
          <title>Nitrous Oxide</title>
          <description>50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Nitrous Oxide: 50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Difficulty with recruitment caused study sponsor to end trial after designated award length; analysis not done</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Placebo: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
        </group>
        <group group_id="B2">
          <title>Nitrous Oxide</title>
          <description>50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Nitrous Oxide: 50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="70" upper_limit="70"/>
                    <measurement group_id="B3" value="70" lower_limit="70" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in MADRS (Montgomery Asberg Depression Rating Scale)</title>
        <description>Change in depressive symptoms on MADRS scale between baseline and day 7 follow up</description>
        <time_frame>up to 1 week</time_frame>
        <population>Difficulty with recruitment caused study sponsor to end trial after designated award length; no analysis done</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Placebo: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
          </group>
          <group group_id="O2">
            <title>Nitrous Oxide</title>
            <description>50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Nitrous Oxide: 50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MADRS (Montgomery Asberg Depression Rating Scale)</title>
          <description>Change in depressive symptoms on MADRS scale between baseline and day 7 follow up</description>
          <population>Difficulty with recruitment caused study sponsor to end trial after designated award length; no analysis done</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Rating Scale-17 Item (Ham-D17)</title>
        <time_frame>up to1week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Young Mania Rating Scale (YMRS) to Assess Emergence of Mania/Hypomania</title>
        <description>Young Mania Rating Scale (YMRS) to assess emergence of mania/hypomania (patients with YMRS scores &gt; 12 will be removed from the trial and recommended for follow up treatment per Psychiatry P.I., i.e., nitrous oxide treatments discontinued)</description>
        <time_frame>up to 1 week</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Profile of Mood States (POMS) Short Form to Assess for Rapid/Instantaneous Changes in Mood/Affect</title>
        <time_frame>up to 1 week</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quick Inventory of Depressive Symptomatology- Self Report (QIDS -SR) Patient-rated Depression Measure</title>
        <time_frame>up to 1 week</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinician Administered Dissociative States Scale (CADSS) for Emergence of Disassociation</title>
        <time_frame>up to 1week</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Brief Psychiatric Rating Scale (BPRS) to Assess Psychotic or Hallucinogenic Behavior</title>
        <time_frame>up to 1 week</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Scale for Suicidal Ideation (SSI) to Assesses for Emergence of Suicidal Thinking</title>
        <time_frame>up to 1 week</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>No participants enrolled in Nitrous Oxide arm</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Placebo: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
        </group>
        <group group_id="E2">
          <title>Nitrous Oxide</title>
          <description>50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Nitrous Oxide: 50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling more cold mostly in feet</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Worsened Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ben J Palanca, MD PhD MSC</name_or_title>
      <organization>Washington University</organization>
      <phone>314-286-0132</phone>
      <email>palancab@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

